Is Janux Therapeutics, Inc. (JANX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.6% / 30% | 114.8% / 30% | 0.8% / 30% | 440.42% / 5% | ✗ NOT HALAL |
| DJIM | 2.6% / 33% | 114.8% / 33% | 0.8% / 33% | 440.42% / 5% | ✗ NOT HALAL |
| MSCI | 2.2% / 33% | 96.5% / 33% | 0.6% / 33% | 440.42% / 5% | ✗ NOT HALAL |
| S&P | 2.6% / 33% | 114.8% / 33% | 0.8% / 33% | 440.42% / 5% | ✗ NOT HALAL |
| FTSE | 2.2% / 33% | 96.5% / 33% | 0.6% / 50% | 440.42% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -1576.7% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -11.5% | |
| Return on Assets (ROA) | -9.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$82M |
| Free Cash Flow | -$83M |
| Total Debt | $22M |
| Debt-to-Equity | 2.3 |
| Current Ratio | 39.0 |
| Total Assets | $1.0B |
Price & Trading
| Last Close | $13.63 |
| 50-Day MA | $13.69 |
| 200-Day MA | $20.91 |
| Avg Volume | 1.4M |
| Beta | 2.9 |
|
52-Week Range
$12.12
| |
About Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Janux Therapeutics, Inc. (JANX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Janux Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Janux Therapeutics, Inc.'s debt ratio?
Janux Therapeutics, Inc.'s debt ratio is 2.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.2%.
What are Janux Therapeutics, Inc.'s key financial metrics?
Janux Therapeutics, Inc. has a market capitalization of $802M, and revenue of $10M. Return on equity stands at -11.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.